Last reviewed · How we verify

Veligrotug (VRDN-001) — Competitive Intelligence Brief

Veligrotug (VRDN-001) (Veligrotug (VRDN-001)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone receptor beta (THR-β) agonist. Area: Cardiovascular.

phase 3 Thyroid hormone receptor beta (THR-β) agonist Thyroid hormone receptor beta (THR-β) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Veligrotug (VRDN-001) (Veligrotug (VRDN-001)) — Viridian Therapeutics, Inc.. Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Veligrotug (VRDN-001) TARGET Veligrotug (VRDN-001) Viridian Therapeutics, Inc. phase 3 Thyroid hormone receptor beta (THR-β) agonist Thyroid hormone receptor beta (THR-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone receptor beta (THR-β) agonist class)

  1. Viridian Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Veligrotug (VRDN-001) — Competitive Intelligence Brief. https://druglandscape.com/ci/veligrotug-vrdn-001. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: